Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Centronuclear Myopathy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. The report provides comprehensive ...
DelveInsight’s, “Obesity - Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug ...
CARLSBAD, Calif. and STRASBOURG, France, Nov. 9, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5 Rx (Dyn101), a ...
The Food and Drug Administration (FDA) has granted Orphan Drug designation to DYN101 (Dynacure) for the treatment of centronuclear myopathies. The Food and Drug Administration (FDA) has granted Orphan ...
Data Bridge Market Research Added new upcoming report title “Centronuclear Myopathies Drug Market Study 2026: Poised For A Strong Growth By Eminent Players – Audentes Therapeutics, Ionis ...
Myopathy is a general medical term used to describe a group of disorders that affect skeletal muscle fibers, leading to muscle weakness. Centronuclear myopathies (CNM) are a group of rare and ...
RYR1 mutations have been mainly implicated in CNM2 associated with autosomal-recessive inheritance. 3, 4 Implication of heterozygous RYR1 mutations in dominant CNM awaits confirmation. MTMR14/hJUMPY ...
(Stuttgart/Braunschweig): ZNM - Zusammen Stark! e. V. an association dedicated to supporting patients with rare muscle conditions known as centronuclear myopathies (CNM), is proud to announce the ...
A study published in Molecular Therapy has presented a promising gene therapy approach for treating centronuclear myopathy (CNM), a rare genetic disorder characterized by muscle weakness and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback